The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
June 21, 2017
Nonviable birth certificates can be filed by the Department of Health’s Bureau of Vital Statistics, effective July 1, 2017. Continue reading
May 5, 2017
Registrations expire on June 30, 2017, Ready to Renew? Click here for information for renewing your registration. Continue reading